Discussion
obesity, obese, overweight, T2DM, weight loss
OBESITY, OBESE, CARDIOVASCULAR DISEASE, HYPERTENSION, DYSLIPIDEMIA
This is the first trial specifically designed to examine the efficacy of PEG-Loxe for weight management and the first trial to investigate PEG-Loxe at a higher dose of 0.3 mg with a fixed-dose-escalation regimen in patients with T2DM. A few studies have reported that a weight-maintenance phase occurred after approximately 12–16 weeks of GLP-1RA treatment (In previous phase 1–3 clinical trials, which enrolled patients with BMIs of 25–27 kg/mWhether directly or indirectly, obesity contributes to the development of several cardiovascular risk factors and comorbidities, including dyslipidemia, hypertension, and cardiovascular disease (The glycemic control effects of 0.1 mg and 0.2 mg PEG-Loxe have been well established in patients with T2DM, as shown by HbA1c reduction ranging from 1.02–1.36% following 12 or 24 weeks of treatment (The safety profile of PEG-Loxe in the present trial was consistent with that in previous trials (This study had several limitations. The open-label design of the present trial may have increased the risk of bias. Furthermore, the clinical trial duration was relatively short, and the full potential of 0.3 mg PEG-Loxe efficacy on weight loss may have been missed. Therefore, additional trials are warranted to assess whether these effects are maintained with long-term 0.3 mg PEG-Loxe treatment.In conclusion, once-weekly subcutaneous PEG-Loxe administration resulted in significantly greater weight loss at 16 weeks, when compared with metformin administration, in overweight or obese patients with T2DM, with lifestyle interventions or OAD therapy. The effects of PEG-Loxe on body weight may provide a treatment option for overweight or obese patients with T2DM.